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Abstract 
Chapter 1: Oxidative Stress.  An overview of oxidative stress and its impact on human 
health.  Various reactive oxygen species and cellular antioxidant defenses are also 
summarized. 
 
Chapter 2: Neuroprostanes.  After a survey of fatty acids and their nomenclature, this 
chapter discusses lipid peroxidation as one of the most significant consequences of 
oxidative stress in vivo.  Lipid metabolites that serve as biomarkers for human diseases 
are also examined. 
 
Chapter 3: First Total Synthesis of 20-F4t-Neuroprostane.  Beginning with a brief 
review of previous neuroprostane syntheses and the Snapper lab’s approach to the 
isoprostanes, the final chapter presents our total synthesis of 20-F4t-neuroprostane.  The 
key steps in the synthesis involve a modified ring-opening cross-metathesis/cross-
metathesis procedure and a one-pot asymmetric double Wittig olefination. 
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Chapter 1:  Oxidative Stress 
As a normal attribute of aerobic metabolism, free radicals are generated as by-
products of regular cellular processes.  Structural damage to organic compounds (e.g., 
lipids, nucleic acids, carbohydrates, proteins) due to an overproduction of free radicals 
results in oxidative stress.  Despite the variety of compounds afflicted, oxidative damage 
is caused by a relatively small number of reactive oxygen species (ROS).1   
 
Formation of common reactive oxygen species 
Most of the molecular oxygen (O2) consumed by respiring cells is reduced to 
water (2H2O) by cytochrome c oxidase in the mitochondrial electron transport chain 
(ETC) without releasing harmful intermediates.2  However, there are both enzymatic and 
spontaneous processes within cells that reduce O2 through donation of a single electron to 
form O2!
- or superoxide – the simplest ROS.  A second single-electron reduction yields 
the peroxide ion, which would immediately protonate at physiological pH to generate 
hydrogen peroxide (H2O2).3,4  H2O2 can readily diffuse across cellular membranes5 to 
react with transitions metals (e.g., Fe2+ and Cu+) to form hydroxide (HO-) and hydroxyl 
radical (HO!) through a process known as the Fenton reaction.6  The most reactive among 
these species, HO! diffuses only a few angstroms before reacting with biological 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Halliwell, B.; Gutteridge, J. M. C. Free Radicals in Biology and Medicine. Oxford: Clarendon, 1999. 
2 “Oxygen toxicity: A radical explanation” Fridovich, I. J. Exp. Biol. 1998, 201, 1203-1209. 
3 “Biological effects of the superoxide radical” Fridovich, I. Arch. Biochem. Biophys. 1986, 247, 1-11. 
4 “Fundamental Aspects of Reactive Oxygen Species, or What’s the Matter with Oxygen?” Fridovich, I. 
Ann. N. Y. Acad. Sci. 1999, 893, 13-18. 
5 “Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes” Bienert, G. P.; 
Moller, A. L. B.; Kristiansen, K. M.; Schulz, A.; Moller, I. M.; Schjoerring, J. K.; Jahn, T. P. J. Bio. Chem. 
2007, 282, 1183-1192. 
6 “The free radical theory of aging matures” Beckman, K. B.; Ames, B. N. Physiol. Rev. 1998, 78, 547-581.!
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molecules.  In comparison, O2!
- is much less reactive and may cross cell membranes to 
act at a distance from the site where it was generated.7  
O2!
- also acts as a chemical precursor to the formation of endogenous peracids.4  
Produced in vivo by the action of nitric oxide synthases on L-arginine, nitric oxide (NO!) 
plays a variety of biological roles involving vasodilation, memory formation and 
inflammation.  NO! reacts rapidly (~1010 M-1!s-1) with O2!
-  to generate peroxynitrite 
(ONOO-), a powerful cellular oxidant.8  This demonstrates another means by which O2!
- 
causes cellular damage leading to oxidative stress.  
 
Targets of endogenous oxidants: lipids, nucleic acids, and proteins 
Acknowledged since antiquity, lipid oxidation leading to rancidity has been a 
problem in the storage of fats and oils.  Food chemists conducted the earliest research on 
the peroxidative chain reactions of biological molecules to account for changes in the 
odor, taste, color, viscosity and solubility of unsaturated lipids after prolonged exposure 
to air.9   However, the significance of lipid peroxidation in biology and medicine was not 
explored until the 1950s.10  Subsequent research has shown oxidative damage by ROS 
leads to changes in the biological properties of lipid membranes, which may result in 
increased tissue permeability and altered cellular function.1  More specifically, lipid 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
7 “Aging, energy, and oxidative stress in neurodegenerative diseases” Beal, M. F. Ann. Neurol. 1995, 38, 
357-366. 
8 “Nitric oxide and oxygen radicals: a question of balance” Darley-Usmar, V.; Wiseman, H.; Halliwell, B. 
FEBS Letters 1995, 369, 131-135. 
9 “The measurement and mechanism of lipid peroxidation in biological systems” Gutteridge, J. M.; 
Halliwell, B. Trends Biochem. Sci. 1990, 15, 129-135. 
10 “Oxidants and human disease: some new concepts” Halliwell, B. FASEB J. 1987, 1, 358-364.!
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peroxidation of the mitochondria has devastating effects on ATP production, enzyme 
activities, and apoptosis initiation.11,12  
Along with lipids, nucleic acids are among the biological macromolecules 
targeted by endogenous oxidants.  DNA is particularly susceptible to iron-catalyzed 
oxidations, such as the Fenton reaction, because iron binds directly to the phosphodiester 
backbone of DNA.13  Thus, the hydroxyl radical (HO!) is the primary ROS responsible 
for oxidative DNA damage, which can result in single and double-stranded DNA 
scissions leading to chromosomal breaks.14  Among syndromes developed from such 
chromosome breaks include Bloom’s syndrome15 and Fanconi’s anemia.16  
Lastly, protein oxidation is of serious concern given their vital roles in regulating 
cell structure, cell signaling and various enzymatic processes.  ROS can directly modify 
peptide bonds and amino acid side chains, especially those consisting of aromatics and 
thiols.17  Unlike lipids and nucleic acids, proteins offer highly diverse targets18 for 
oxidative damage that can result in many different outcomes such as misfolding, 
modification of enzyme activity,19 modification to signal transfer, alterations in 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
11 “Mitochondria and apoptosis” Green, D. R.; Reed, J. C. Science 1998, 281, 1309-1312.  
12 “Neural apoptosis” Bredesen, D. E. Ann. Neurol. 1995, 38, 839-851. 
13 “Molecular targets of oxidative stress” Avery, S. V. Biochem. J. 2011, 434, 201-210. 
14 “Biochemistry of oxidative stress” Sies, H. ACIE 1986, 25, 1058-1071. 
15 “New aspects on chromosomal instability: Chromosomal break-points in Fanconi anemia patients co-
localize on the molecular level with fragile sites” Schoder, C.; Liehr, T.; Velleuer, E.; Wilhelm, K.; 
Blaurock, N.; Weise, A.; Mrasek, K. Int. J. Oncol. 2010, 36, 307-312. 
16 “Depletion of the bloom syndrome helicase stimulates homology-dependent repair at double-strand 
breaks in human chromosomes” Wang, Y.; Smith, K.; Waldman, B. C.; Waldman, A. S. DNA Repair 
ASAP 2011. 
17 “Comparative free radical chemistry in the radiolytic deamination and dephosphorylation of bio-organic 
molecules. II. Oxygenated solutions” Garrison, W. M. Free Radic. Biol. Med. 1989, 7, 171-175. 
18 “Protein oxidation and cellular homeostasis: Emphasis on metabolism” Cecarini, V.; Gee, J.; Fioretti, E.; 
Amici, M.; Angeletti, M.; Eleuteri, A. M.; Keller, J. N. Biochim. Biophys. Acta 2007, 1773, 93-104. 
19 “Activation of soluble guanylate cyclase from rat lung by incubation or by hydrogen peroxide” White, A. 
A.; Crawford, K. M.; Patt, C. S.; Lad, P. J. J. Biol. Chem. 1976, 251, 7304-7312. 
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intercellular calcium and potassium,20 and increase susceptibility to degradation and 
removal. 
 
Cellular antioxidant defenses 
In addition to an increase in the generation of endogenous free radicals, oxidative 
stress also occurs through a decrease in cellular antioxidant defenses.  Common 
antioxidants range from compounds such as vitamin C and vitamin E to enzymes 
including catalases, peroxidases, and superoxide dismutases (SODs).1   
 
FIGURE 1.1.  Structures of Vitamins C & E. 
Micronutrients, such as vitamin C and vitamin E (FIGURE 1.1), play an 
important role in the prevention of cellular oxidative damage by scavenging ROS.  
Vitamin C is a known reducing agent in aqueous environments and works in synergy 
with lipid-soluble antioxidants like vitamin E.21  For instance, "-tocopherol, the most 
active form of vitamin E, protects against lipid peroxidation by donating a hydrogen atom 
(H!) to either a lipid radical (R!) or lipid peroxyl radical (ROO!).  The comparatively 
benign and stable "-tocopherol radical is then reduced back to "-tocopherol by, among 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
20 “The role of oxidative stress in chemical carcinogenesis” Klaunig, J. E.; Xu, Y.; Isenberg, J. S.; 
Bachowski, S.; Kolaja, K. L.; Jiang, J.; Stevenson, D. E.; Walborg Jr., E. F. Environ. Health Perspect. 
1998, 106, 289-295. 
21 “Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill 
patients” Schorah, C. J.; Downing, C.; Piripitsi, A.; Gallivan, L.; Al-Hazaa, A. H.; Sanderson, M. J.; 
Bodenham, A. Am. J. Clin. Nutr. 1996, 63, 760-765. 
The !-tocopherol form of vitamin E
OH
OH
OHO
O
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O
OH
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other species, vitamin C.22  Additional biomedical research has established links between 
disease progression and low plasma levels of vitamins C and E in a broad range of 
critically ill and injured patients.23 
Enzymes, particularly SODs, are the most effective intracellular antioxidants.  In 
humans, three main classes of SODs with distinct protein folds and catalytic metal ions 
have evolved: Cu,Zn-SOD (SOD1), mitochondrial Mn-SOD (SOD2), and extracellular 
Cu,Zn-SOD (SOD3).1  Each SOD catalyzes the disproportionation of O2!
- to O2 and 
H2O2.  H2O2 is then either converted to H2O and O2 by catalases, or reduced to H2O by 
peroxidases.2   
Catalases, which are largely located within cells in peroxisomes, have some of the 
highest turnover rates among all enzymes.  In 2001, Young and Woodside observed that a 
single molecule of catalase decomposes millions of H2O2 molecules every second 
without generating free radicals.24  As an FeIII-based porphyrin tetramer,25 catalase 
operates by first reacting with H2O2 to generate an oxoferryl porphyrin cation radical         
(Por!+–FeIV=O) and H2O.  This high-valent iron intermediate then rapidly reacts (a highly 
exothermic reaction) with a second molecule of H2O2 to generate O2 and H2O.26 
One essential family of peroxidases in human cells is the glutathione peroxidases 
(GPx).   In the process of reducing H2O2 to H2O, GPx simultaneously oxidizes 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
22 “Vitamin C: Basic metabolism and its function as an index of oxidative stress” Kojo, S. Curr. Med. 
Chem. 2004, 11, 1041-1064. 
23 “Antioxidants in critical illness” Bulger, E. M.; Maier, R. V. Arch. Surg. 2001, 136, 1201-1207.!
24 “Antioxidants in health and disease” Young, I. S.; Woodside, J. V. J. Clin. Pathol. 2001, 54, 176-186. 
25 “Catalase: A tetrameric enzyme with four tightly bound molecules of NADPH” Kirkman, H. N.; Gaetani, 
G. F. Proc. Natl. Acad. Sci. USA 1984, 81, 4343-4347. 
26 “The molecular mechanism of the catalase reaction” Alfonso-Prieto, M.; Biarnes, X.; Vidossich, P.; 
Rovira, C. J. Am. Chem. Soc. 2009, 131, 11751-11761. 
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monomeric glutathione (GSH) to glutathione disulfide (GS-SG).27  The cellular ratio of 
GS-SG/GSH is regarded as a sensitive measurement of oxidative stress given that an 
increase in this ratio is an indication of high GPx activity.28     
 
Human illnesses associated with oxidative stress 
In 1956, Denham Harman postulated29 “aging and the degenerative diseases 
associated with it are attributed basically to the deleterious side attacks of free radicals on 
cell constituents and on the connective tissue.”  A prior 1954 study using paramagnetic 
resonance spectroscopy to detect free radicals in living matter30 led Harman to 
hypothesize that endogenous free radical generation occurs as a byproduct of enzymatic 
redox chemistry and that the principles of peroxidative chain reactions were analogous to 
those of in vitro polymer chemistry.  This theory, now recognized as the Free Radical 
Theory of Aging, gained credibility with the 1969 discovery of SODs31 and continues to 
drive research efforts linking oxidative stress to the pathogenesis of a number of human 
illnesses,32 including vascular diseases, inflammatory conditions, cancers, and 
neurodegenerative disorders. 
 Over the last three decades, cell culture and animal studies have provided clear 
evidence of a direct correlation between oxidative stress and the progression of vascular !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
27 “Glutathione peroxidase family – an evolutionary overview” Margis, R.; Dunand, C.; Teixeira, F. K.; 
Margis-Pinheiro, M. FEBS Journal 2008, 275, 3959-3970. 
28 “Acute immune response in respect to exercise-induced oxidative stress” Vider, J.; Lehtmaa, J.; 
Kullisaar, T.; Vihalemm, T.; Zilmer, K.; Kairane, C.; Landor, A.; Karu, T.; Zilmer, M. Pathophysiology 
2001, 7, 263-270. 
29 "Aging: a theory based on free radical and radiation chemistry" Harman, D.  J. Gerontol. 1956, 11, 298-
300. 
30 “Free radicals in biological materials” Commoner, B.; Townsend, J.; Pake, G. E. Nature 1954, 174, 689-
691. 
31 “Superoxide dismutase: An enzymic function for erythrocuprein (hemocuprein)” McCord, J. M.; 
Fridovich, I. J. Biol. Chem. 1969, 244, 6049-6055. 
32 “Oxidative stress and human diseases: Origin, link, measurement, mechanism and biomarkers” 
Giustarini, D.; Dalle-Donne, I.; Tsikas, D.; Rossi, R. Cr. Rev. Cl. Lab. Sc. 2009, 46, 241-281.!
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diseases.33  The formation of ROS species has shown a rapid and profound increase in the 
post-ischemic heart, and serves as a primary mechanism for post-ischemic damage.34  
Thus, while immediate reperfusion of ischemic myocardium is essential to prevent 
further myocardial injury, reperfusion often results in a unique form of myocardial 
damage inflicted by ROS.  Ongoing efforts in cardiovascular research aim to discover 
effective radical scavengers, such as enzymes35 or small molecules,36 to salvage heart 
muscle at risk in acute coronary syndromes.37 
 Oxidative stress occurs in patients with inflammatory conditions, such as 
rheumatoid arthritis (RA), and plays an important role in both the inflammation and 
destruction of cartilage and bone.38  Thioredoxin (TRX), a ubiquitous redox-active 
protein, is a quantifiable biomarker used to access oxidative stress in RA patients and 
may provide a new understanding for currently untreatable chronic inflammatory joint 
diseases.39   
 Direct oxidative damage to DNA by ROS, especially HO!, has been linked to 
carcinogenesis by affecting a variety of cellular processes including cell proliferation, 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
33 “Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury” 
Papaharalambus, C. A.; Griending, K. K. TCM 2007, 17, 48-54. 
34 “Measurement and characterization of postischemic free radical generation in the isolated perfused heart” 
Zweier, J. L.; Kuppusamy, P.; Williams, R.; Rayburn, B. K.; Smith, D.; Weisfeldt, M. L.; Flaherty, J. T. J. 
Biol. Chem. 1989, 264, 18890-18895. 
35 “Canine myocardial reperfusion injury: Its reduction by the combined administration of superoxide 
dismutase and catalase” Jolly, S. R.; Kane, W. J.; Bailie, M. B.; Abrams, G. D.; Lucchesi, B. R. Circ. Res. 
1984, 54, 277-285. 
36 “Beneficial effects of mannitol administration during reperfusion after ischemic arrest” Lucas, S. K.; 
Gardner, T. J.; Flaherty, J. Y.; Bulkley, B. H.; Elmer, E. B.; Gott, V. L. Circulation 1980, 62, 134-141. 
37 “The role of oxidants and free radicals in reperfusion injury” Zweier, J. L.; Hassen Talukder, M. A. 
Cardiovasc. Res. 2006, 70, 181-190. 
38 “Hypoxia, oxidative stress and rheumatoid arthritis” Mapp, P. I.; Grootveld, M. C.; Blake, D. R. Br. Med. 
Bull. 1995, 51, 419-436. 
39 “Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis” Jikimoto, T.; 
Nishikubo, Y.; Koshiba, M.; Kanagawa, S.; Morinobu, S.; Morinobu, A.; Saura, R.; Mizuno, K.; Kondo, S.; 
Toyokuni, S.; Nakamura, H.; Yodoi, J.; Kumagai, S. Mol. Immunol. 2001, 38, 765-772. 
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senescence, and metastasis.40  Changes in cell proliferation result from the modulation of 
various cell-cycle proteins, like p53 and ATM (ataxia telangiectasia mutated), by high 
levels of endogenous ROS.41,42  In terms of cell senescence, the ability of mitochondrial 
AIF (apoptosis inducing factor) protein to oxidize NADH and consequently produce ROS 
contributes to the viability of selected carcinoma cell lines.43  Lastly, studies examining 
peroxidation end-products have shown that metastatic human tumor cells produce greater 
levels of ROS than primary malignant cells, which may actually reduce metastasis by 
triggering an increase in cellular antioxidant defenses.44,45  
 Despite its relatively small mass, the brain accounts for approximately 20% of the 
body’s total basal oxygen consumption.46  This disproportionately high oxygen intake 
leads to the exposure of brain cells to an environment with considerable ROS compared 
to other areas of the body.  Thus, evidence has emerged suggesting that oxidative damage 
plays a key pathogenic role in neurodegenerative disorders.  For instance, post-mortem 
examinations of Parkinsonian patients have revealed significantly diminished levels of 
antioxidants and antioxidant enzymes, and highly increased levels of lipid peroxidation 
adducts, protein oxidation, oxidative DNA damage as well as other markers of oxidative 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
40 “Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression 
to cancer” Wiseman, H.; Halliwell, B. Biochem. J. 1996, 313, 17-29. 
41 “Savior and slayer; the two faces of p53” Bensaad, K.; Vousden, K. H. Nat. Med. 2005, 11, 1278-1279. 
42 “Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells” Ito, 
K.; Hirao, A.; Arai, F.; Takubo, K.; Matsuoka, S.; Miyamoto, K.; Ohmura, M.; Naka, K.; Hosokawa, K.; 
Ikeda, T. Nat. Med. 2006, 12, 446-451. 
43 “AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells” 
Urbano, A.; Lakshmanan, U.; Choo, P. H.; Kwan, J. C.; Ng, P. Y.; Guo, K.; Dhakshinamoorthy, S.; Porter, 
A. EMBO J. 2005, 24, 2815-2826. 
44 “Oxidative stress and cancer: have we moved forward?” Halliwell, B. Biochem. J. 2007, 401, 1-11. 
45 “Oxidative damage and cancer” Oberley, T. D. Am. J. Pathol. 2002, 160, 403-408. 
46 “Energetic basis of brain activity: implications for neuroimaging” Shulman, R. G.; Rothman, D. L.; 
Behar, K. L.; Hyder, F. Trends Neurosci. 2004, 27, 489-495. 
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injury.47  Elevated levels of oxidative stress are also found in the cerebrospinal fluid of 
patients suffering from amyotrophic lateral sclerosis (ALS) and infarcted portions of 
stroke victims’ brains.48,49  Lastly, the dysregulation of transition metal ion homeostasis 
and oxidative stress in brain cells substantially impacts the accumulation of amyloid 
# plaque deposits - a putative factor in Alzheimer’s disease pathogenesis.50 
 
Conclusion 
Oxidative stress occurs by either an increase in the production of endogenous 
ROS, a decrease in cellular antioxidant defenses, or a combination of both.  Decades of 
evidence suggest a direct link between oxidative stress and the progression of a wide 
range of human maladies.  However, the precise role of oxidative stress in human 
pathophysiology is not fully understood. 
  
 
 
 
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
47 “Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies 
in humans” Castellani, R. J.; Perry, G.; Siedlak, S. L.; Nunomura, A.; Shimohama, S.; Zhang, J.; Montine, 
T.; Sayre, L. M.; Smith, M. A. Neurosci. Lett. 2002, 319, 25-28. 
48 “Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress–induced death 
of motor neurons in amyotrophic lateral sclerosis” Cutler, R. S.; Pedersen, W. A.; Camandola, S.; 
Rothstein, J. D.; Mattson, M. P. Ann. Neurol. 2002, 52, 448-457. 
49 “Potential markers of oxidative stress in stroke” Cherubini, A.; Ruggiero, C.; Polidori, M. C.; Mecocci, 
P. Free Radical Bio. Med. 2005, 39, 841-852.  
50 “Mechanisms of neural and behavioral dysfunction in Alzheimer’s disease” Wesson, D. W.; Nixon, R. 
A.; Levy, E.; Wilson, D. A. Mol. Neurobiol. 2011, 43, 163-179. 
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Chapter 2:  Neuroprostanes 
Brain cells are highly susceptible to the detrimental effects of oxidative stress due 
to their high metabolic rate, low antioxidant levels, poor regenerative ability, high 
intracellular concentrations of transition metals able to catalyze the formation of ROS, 
and rich composition of polyunsaturated fatty acids (PUFAs) prone to peroxidation.51  
End-products from lipid peroxidation often exert potent biological activity and are 
regarded as sensitive biomarkers for oxidative stress.  Neuroprostanes represent a unique 
class of these lipid peroxidation products. 
 
Fatty acids 
 Essential fatty acids (EFAs) are fatty acids required for good health but must be 
obtained through diet because they cannot be synthesized by the body.  EFAs are vital for 
normal growth and development, and optimal function of several major organ systems.52 
They primarily serve as dietary precursors for the formation of a variety of signaling 
molecules (e.g., classic eicosanoids) that affect many biological processes including 
inflammation, blood pressure, uterine contraction, bronchial constriction, retinal health, 
and brain function.53   
 The only two known EFAs for humans are "-linolenic acid (ALA, C18:3, $-3) 
and linoleic acid (LA, C18:2, $-6) (FIGURE 2.1). 
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FIGURE 2.1.  Structures of "-linolenic acid and linoleic acid. 
 According to omega-x fatty acid nomenclature rules, EFAs are named based on the 
location of the first double bond in the chain from the terminal methyl group.  
Additionally, fatty acids are less commonly named by lipid numbers (C:D) where C 
represents the total number of carbons while D is the number of alkenes present in the 
aliphatic chain. 
As the parent fatty acid of the $-6 class, linoleic acid is elongated and desaturated 
through sequential enzymatic steps to form arachidonic acid (AA, C20:4, $-6).  
Similarly, "-linolenic acid, the parent fatty acid of the $-3 class, undergoes elongation 
and desaturation by the same enzymes to form eicosapentaenoic acid (EPA, C20:5, $-
3).54  Further enzymatic elongation and desaturation of EPA gives docosahexaenoic acid 
(DHA, C22:6, $-3) (FIGURE 2.2).55   
 
FIGURE 2.2.  Structures of arachidonic, eicosapentaenoic, and docosahexaenoic 
acids. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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 Both EPA and DHA represent the most physiologically important members of the 
$-3 fatty acid class.  Research, however, has shown that the conversion of "-linolenic 
acid into its longer chain derivatives is slow and inefficient in adult humans.56  Evidence 
suggests that dietary supplementation with foods rich in $-3 fatty acids, such as marine 
fish oil, is perhaps the best method to increase human cell and tissue levels of EPA and 
DHA.57 
 
Lipid peroxidation products 
As previously mentioned, one of the most significant consequences of oxidative 
stress is lipid peroxidation.  During a 1988 investigation of the effects of oxidative stress 
on human plasma, Roberts et al. discovered significant quantities of lipid metabolites 
generated from the non-enzymatic, free-radical induced peroxidation of arachidonic acid, 
an $-6 fatty acid ubiquitous in phospholipid membranes throughout the body.58  
Subsequent studies on these lipid oxidation products, now referred to as isoprostanes 
(FIGURE 2.3), led to their isolation, characterization, and detection in vivo.  
Isoprostanes currently serve as the best available biomarker to assess oxidative stress 
linked to a wide range of human disorders59 such as cardiovascular disease,60 diabetes,61 
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cancer,62 and chronic obstructive pulmonary disease (COPD).63  Perhaps of equal 
importance, several isoprostanes exert potent biological activity.64   
 
FIGURE 2.3. Isoprostanes: lipid metabolites derived from arachidonic acid. 
In 1998, two studies65,66 revealed a new class of isoprostane-like compounds 
derived from the free-radical induced peroxidation of DHA, an $-3 fatty acid required for 
healthy brain function and development.  Brain tissue mostly consists of glial cells or 
glia, and neurons.  Glia, meaning “glue” in Greek, are primarily responsible for providing 
the physical support for neurons, maintaining homeostasis, and supplying surrounding 
cells with oxygen and nutrients.  Neurons are cells known to possess and transmit 
information throughout the body by electrical excitation and chemical signaling.  
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Herculano-Houzel and company used their novel isotropic fractionator method67 to 
estimate that the ratio of glial cells to neurons is ~1:1 throughout the human brain and 
~3:2 in cerebral gray matter.68  Brain tissue, gray matter in particular, is highly enriched 
with DHA where it comprises ~40% of the total PUFA population, and nearly 50% of the 
weight of neuronal membranes.69   
 
Figure 2.4.  Neuroprostanes: lipid metabolites derived from docosahexaenoic acid.66 
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Given this high concentration of DHA in neuronal tissue, quantification of 
isoprostane-like compounds derived from DHA, which Roberts66 et al. termed 
neuroprostanes (FIGURE 2.4), provides a unique biomarker of oxidative stress in the 
central nervous system.  While neuroprostanes, like other lipid metabolites, are believed 
to play an active role in the human body, the biological activities of the various 
neuroprostane regioisomers has yet to be elucidated.70  
 
Nomenclature 
The discovery of the isoprostanes created an urgent need for a concise 
nomenclature of lipid metabolites.  Two systems were concurrently devised by Rokach et 
al.71,72 in 1996 (later revised in 1997), and by Taber, Morrow, and Roberts73 in 1997.  A 
useful feature of the Rokach nomenclature is that the formation pathway of the 
metabolite is coded in the name by roman numerals.  However, the Taber/Roberts system 
is more straightforward, and is approved by the IUPAC; thus it will be used throughout 
this thesis. 
 In the Taber/Roberts nomenclature system, the first number indicates the position 
of the allylic alcohol on the side chain, with C1 being the carboxyl group (FIGURE 2.4).  
The capital letter indicates the lipid metabolite’s level and/or location of oxidation, which 
is shown in FIGURE 2.5.   !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Figure 2.5.  Classification according to level and location of oxidation. 
To further explain the Taber/Roberts nomenclature system, FIGURE 2.6 illustrates the 
complete, stereodefined 20-F4-neuroprostane library. 
 
Figure 2.6.  Predicted 20-F4-neuroprostane isomers. 
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The subscripted number (4, in this case) designates the total amount of carbon-carbon 
double bonds in the molecule and the subscripted lowercase letter signifies the 
relationship between the syn-1,3 diol and the syn-1,2 alkyl chains as either trans (t) or cis 
(c).  The default configuration is shown as the 20-F4t-neuroprostane and 20-F4c-
neuroprostane.  Inversion of the allylic alcohol is denoted with the prefix “carbon 
number-epi-” while enantiomers of default structures are assigned “ent-” as the prefix. 
 
Syn relationship of alkyl chains 
 In the absence of enzymes, free radical-induced lipid peroxidation operates with a 
high selectivity toward the formation of products containing syn alkyl chains (as 
predicted for the 20-F4-neuroprostanes shown in FIGURE 2.6).  Porter and Funk74 first 
observed this phenomenon while reacting methyl "-linolenate with oxygen in benzene 
but the configuration of these compounds was not established unequivocally.  O’Connor 
et al.75 later investigated the cyclization behavior of linolenic acid hydroperoxides after 
reaction with oxygen in carbon tetrachloride to definitively identify the preferential syn 
diastereoselectivity of alkyl chains (FIGURE 2.7).   
 
Figure 2.7.  Favored Syn relationship of alkyl chains observed in lipid peroxidation. 
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Relative stereochemistry for the bicyclic endoperoxides was established by reduction to 
the corresponding triols and correlating 1H and 13C NMR spectra to established literature 
precedent.76 
 Beckwith and Schiesser77 utilized force field calculations to examine the cis-
dialkyl selectivity observed for 5-exo-trig cyclizations of substituted 5-hexenyl radicals.  
Spellmeyer and Houk78 expanded this theoretical study with the inclusion of boat-like 
transition structures used to predict the regio- and stereoselectivities of radical 
cyclizations.  Together, the two groups devised the Beckwith-Houk transition state model 
used to explain the formation of syn-1,2 dialkyl chains (FIGURE 2.8). 
 
Figure 2.8.  20-F4-neuroprostanes: Beckwith-Houk favored geometries for 5-exo-trig 
radical cyclization. 
It is worthy to note that both transition states place the alkyl substituents in pseudo-
equatorial positions, which the authors credit as the source of the syn-1,2 selectivity.  
Also, the chair-equatorial transition state leads to the cis relationship between the syn-1,3 
diol and the syn-1,2 dialkyl chains while the boat-equatorial transition state leads to the 
trans relationship. 
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Alzheimer’s disease and neuroprostanes 
Alzheimer’s disease (AD), the most common form of dementia, is an incurable, 
progressive neurodegenerative disorder.  AD affects roughly 20 million people 
worldwide with a rate of incidence that doubles every five years beyond the age of 65.79  
Estimates suggest prevalence will quadruple by 2050, forecasting that 1 in 85 people 
worldwide will be living with the disease.80  Diagnosis of AD is often inexact: 
neurologists primarily use clinical criteria requiring a memory disorder and impairment 
in either social function or activities of daily living, supported by laboratory 
investigations and neuroimaging analysis.81  Despite tremendous efforts in biomedical 
research, a definitive diagnosis is often only achieved after postmortem examination.  
Thus, there remains an immense need to identify neuropathological biomarkers of AD to 
enhance early diagnosis as well as assess disease progression and treatment response. 
Several studies have reported increased oxidative stress in certain regions of the 
brain in patients with AD.82,83  Morrow et al. were able to detect increased levels of F4-
neuroprostanes in the brain tissue and cerebrospinal fluid of patients suffering from AD 
when compared to age-matched controls.66  In fact, F4-neuroprostane levels in post-
mortem temporal lobe tissue from AD patients were 2.1 times higher than levels observed 
in control tissue.  Recent efforts have been made to synthesize internal standards, such as 
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stereospecific isotope-labeled neuroprostanes (FIGURE 2.9), to accurately quantify 
neuroprostanes levels produced in vivo.84,85 
 
Figure 2.9.  Previously synthesized mass-tagged neuroprostanes.84,85 
 
Biosynthesis of the neuroprostanes 
Neuroprostanes are formed non-enzymatically in vivo by the oxidative attack of 
free ROS on DHA.  Although the mechanism of DHA oxidation is more complex than 
arachidonic acid, the same free radical mechanism can be applied to predict 
neuroprostane regioisomers and their relative abundance.86  FIGURE 2.10 illustrates the 
two proposed mechanisms for the formation of the 20-F4-neuroprostanes. 
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2.10.  Endoperoxide & dioxetane mechanisms of 20-F4-neuroprostane biosynthesis. 
The endoperoxide mechanism initiates by hydrogen atom abstraction at the C18 
position of DHA to give a resonance stabilized doubly allylic radical.  Molecular oxygen 
adds at the C16 position to form the peroxy radical that undergoes successive 5-exo-trig 
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cyclizations followed by trapping with another oxygen molecule to give the bicyclic 
peroxide.  Reductase enzymes reduce the peroxide to give the allylic alcohol in the final 
product.   
The dioxetane mechanism also begins with hydrogen atom abstraction at the C18 
position of DHA but O2 adds at the opposite end of the resonance stabilized pentadienyl 
radical (the C20 position).  A subsequent 4-exo-trig cyclization forms the 1,2-dioxetane-
like intermediate, which is trapped by an additional oxygen molecule to form the peroxy 
radical.  Two successive 5-exo-trig cyclizations followed by opening of the dioxetane 
ring gives the bicyclic peroxide that is ultimately reduced by reductase enzymes to afford 
the 20-F4-neuroprostane. 
Corey and Wang87 first proposed the dioxetane mechanism for isoprostane 
biosynthesis after observing an unexpected oxidation product while devising a 
biomimetic synthesis of the prostaglandins.  Rokach et al.88 pose the dioxetane 
mechanism as a worthy alternative to explain the formation of various isoprostane 
regioisomers.  However, Morrow and Porter89 suggest that only the endoperoxide 
mechanism operates after they analyzed the chirality of isoprostane products formed from 
an optically pure peroxyl radical.  Since ROS-induced peroxidation is chemical in nature 
and non-enzymatic, the biological mechanism continues to be a topic of debate.70   
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According to the endoperoxide mechanism of biosynthesis, eight possible 
regioisomeric neuroprostanes (FIGURE 2.11) could be formed from five different bis-
allylic carbons (C6, C9, C12, C15, C18) of DHA. 
 
Figure 2.11.  Predicted endoperoxide pathway for the formation of neuroprostane 
regioisomers by non-enzymatic peroxidation of DHA. 
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It is important to note that hydrogen atom abstraction at the C9, C12, or C15 position of 
DHA leads to either the 7/11-series, 10/14-series, or 13/17-series of neuroprostanes, 
respectively.  Each of these pentadienyl radicals ultimately leads to two different 
neuroprostane regioisomers.  However, hydrogen abstraction at the C6 or C18 position 
leads to either the 4-series or 20-series, respectively.  Morrow and company argue that 
only one, opposed to two, neuroprostane regioisomers is generated because the radical 
precursors leading to these two 4-series and 20-series neuroprostanes cannot further 
cyclize to form 1,2-dioxolane-like intermediates.  Thus, both the 4-series and 20-series 
neuroprostanes are generated in greater amounts in comparison to other regioisomers.  
Analysis of neuroprostane quantities formed both in vivo and in vitro supported the 
hypothesis that the 4-series and 20-series are in fact preferentially generated.86   
 
Conclusion 
 Research over the last two decades suggests that PUFAs in brain tissue are highly 
susceptible to oxidative damage by endogenous ROS.  Lipid peroxidation products, such 
as neuroprostanes, are sensitive biomarkers of oxidative stress and are believe to play an 
active role in the human body.  As the prevalence of age-related neurodegenerative 
disorders continues to rise, quantification of neuroprostanes found in vivo may provide 
clinicians with precise methods for early diagnosis, disease progression, and treatment 
response. 
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Chapter 3:  First Total Synthesis of 20-F4t-Neuroprostane 
 The discovery of regioselectivity in the formation of neuroprostanes allows 
biological studies to focus on the most abundantly generated isomers (4-series and 20-
series) to determine their role in the pathophysiological processes associated with DHA 
peroxidation and oxidative stress.  Chemical synthesis of the neuroprostanes is essential 
to fully elucidate the biological activity and functional role of these lipid metabolites.  
Since the 20-series had not been previously synthesized and poses an interesting 
challenge to synthetic chemists, we decided to focus our efforts on the enantioselective 
total synthesis of 20-F4t-neuroprostane. 
 
Past chemical syntheses of neuroprostanes 
In 2000, Durand et al.90 completed the first neuroprostane total synthesis in 18 
steps (FIGURE 3.1).  Their approach began by accessing a silyl protected cyclopentane 
core from diacetone-D-glucose in 9 steps.   
 
Figure 3.1. Total synthesis of 4(RS)-F4t-neuroprostane methyl ester. 
Both side chains were added to the cyclopentane core through the use of Wittig 
olefinations (Horner-Wadsworth-Emmons modification generated the E-alkene).  Durand 
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J.-C. Tetrahedron Lett. 2000, 41, 3859-3862. 
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and company91 later applied the same approached by varying their Wittig reagents to 
synthesize the 4-F3t-neuroprostane and its 4-epimer (FIGURE 3.2) in 17 steps.  Both 
neuroprostane diastereomers were ultimately separated at the end of their synthesis by 
column chromatography (approximately 30% mixed fractions). 
 
Figure 3.2.  4-F3t-neuroprostane and its 4-epimer. 
Most recently, Durand and Galano85 synthesized a deuterium-labeled 4-F4t-neuroprostane 
in 20 steps.  The core cyclopentane ring was accessed starting from 1,3-cyclooctadiene 
and again the side chain containing an E-olefin was established using a Horner-
Wadsworth-Emmons reagent.  Subsequent reaction with an unstabilized Wittig reagent 
gave the skipped diyne side chain, which was selectively reduced (cis deuterated) by 
Brown’s catalyst.92 
 
Figure 3.3.  Skipped diyne approach to mass-tagged neuroprostanes. 
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Brown’s nickel-based catalyst92 proved to accomplish the stereoselective semi-
deuteration of skipped diynes more effectively than several other methods, such as 
Lindlar’s catalyst. 
 In 2002, Quan and Cha93 published a 19-step synthesis of 17-F4c-neuroprostane as 
summarized in FIGURE 3.4.  
 
Figure 3.4.  Cha’s approach to the total synthesis of 17-F4c-neuroprostane. 
The key step in their approach utilized a palladium-catalyzed intramolecular cross-
coupling reaction involving Pd(OAc)2, dppp, Et3N, and H2O in DMF at 80 °C to produce 
the bicyclic product in 55% yield.  The skipped diene was added through a late stage 
Wittig reaction, which, after deprotection, completed the first synthesis of a 17-series 
neuroprostane. 
 In a 2007 report, Taber et al.94 synthesized all four enantiomerically pure 13-F4t-
neuroprostanes in 21 steps each.  The authors proposed that their synthetic strategy could 
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easily be adapted to the 13-F4c-neuroprostanes (cis series) as well.  As illustrated in 
FIGURE 3.5, the cis-dialkyl stereochemistry of the cyclopentane was established using a 
thermal-mediated Alder ene reaction.   
 
 
Figure 3.5.  Taber’s 21 step synthetic route the trans 13-series neuroprostanes. 
Another key step involved a Sonogashira-type cross coupling reaction between a terminal 
alkyne and an alkyl bromide.  Subsequent reduction with Brown’s nickel-based 
catalyst,92 deprotection, and saponification successfully produced 13-F4t-neuroprostane.  
The separation of diastereomers along their synthetic route allowed the other three trans 
stereoisomers to be synthesized with high enantiomeric purity. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
94 “A potential route to neuroprostanes and isoprostanes: Preparation of the four enantiomerically pure 
diastereomers of 13-F4t-NeuroP” Taber, D. F.; Reddy, P. G.; Arenson, K. O. J. Org. Chem. 2008, 73, 3467-
3474.!
R3SiO
R3SiO
OEt
O
OBn
!
R3SiO
R3SiO
HO
HO
Me
HO2C
OH
13-F4t-neuroprostane
R3SiO
R3SiO
Me
OH
CO2Et
OBn
R = tBu, Ph, Ph
+
Br
CO2Et
R3SiO
R3SiO
Me
OH
EtO2C
Cross-
Coupling
1) Brown's Cat.
2) Deprotection
3) Saponification
!#*!
 Also in 2007, Zanoni and Vidari95 described the first enantioselective approach to 
the synthesis of cyclopentenone, or A-ring, neuroprostanes.  They reported a 14 step 
convergent synthesis of 14-A4t-neuroprostane (summarized in FIGURE 3.6). 
  
Figure 3.6.  Zanoni and Vidari’s convergent synthesis of 14-A4t-neuroprostane. 
Their synthetic strategy features a Julia-Kocienki olefination to install the side chain 
containing an allylic alcohol.  Subsequently, a late stage Wittig olefination and several 
function group manipulations were performed to furnish the desired 14-A4t-
neuroprostane.   
 
Previous isoprostane syntheses from the Snapper Lab 
 Research in the Snapper lab has shown that functionalized cyclobutenes are 
highly versatile and useful precursors for target-oriented synthesis.  As part of an ongoing 
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effort in this area, Schrader and Snapper96 completed a stereodivergent synthesis of all 
eight isomers of the 15-F2-isoprostanes (SCHEME 3.1).  The key cyclobutenes 3.02 and 
3.03 were synthesized from a [2+2] photocycloaddition between cyclopentenone 3.01 and 
acetylene.  Ring-opening cross-metathesis (ROCM), promoted by Grubbs’ second-
generation catalyst, of cyclobutenes 3.02 and 3.03 with excess oct-1-ene-3-ol gives a 
mixture of diastereomers and olefin isomers.  
 
Scheme 3.1.  Stereodivergent synthesis of all eight 15-F2-isoprostane isomers. 
These stereoisomers were then resolved to generate racemic enones 3.04 and 3.05.  
Subsequent asymmetric reduction and separation of diastereomers led to the synthesis of 
four cis and four trans 15-F2-isoprostanes in an enantiomerically enriched fashion.  This 
15-step synthesis (longest linear sequence) marked the first stereodivergent approach to 
all eight isomers of any regiochemical class of isoprostanes. 
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 For each of the eight 15-F2-isoprostane isomers, whole blood platelet aggregation 
inhibition assays were performed to gain a better understanding of their biological 
activity.  Only two of the eight isomers demonstrated complete inhibition of blood 
platelet aggregation and, at lower concentrations, ent-15-epi-F2t-isoprostane was 
significantly more active than the known inhibitor 15-F2t-isoprostane (FIGURE 3.7).97 
 
Figure 3.7.  Results from whole blood platelet aggregation inhibition assays of the 
15-F2-isoprostanes. 
This new antiaggregatory activity discovered by initial biological studies inspired 
Shizuka and Snapper98 to modify the route to the 15-F2-isoprostanes in order to 
selectively synthesize ent-15-epi-F2t-isoprostane and a D4-labeled analogue (SCHEME 
3.2). 
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Scheme 3.2.  Selective synthesis of a biologically active 15-F2-isoprostane isomer and 
a tetradeuterated derivative. 
Their overall 14-step selective synthesis began with the enzymatic desymmetrization of 
meso-diol 3.06 followed by functional group manipulations to generate the 
enantiomerically pure enone 3.01.  A photochemical [2+2] cycloaddition between 
cyclopentenone 3.01 and acetylene forms a functionalized cyclobutene that was 
selectively reduced with DIBAL-H to generate the mono-protected 1,3-diol 3.07.  ROCM 
under an atmosphere of ethylene produced divinyl compound 3.08.  By using either oct-
1-en-3-one or its tetradeuterated derivative as the cross partner, enones 3.09 and 3.10 
were furnished by a ruthenium-catalyzed cross-metathesis (CM).  Several additional steps 
were required to install the second side-chain and complete the selective syntheses of ent-
15-epi-F2t-isoprostane and its D4-labeled analogue. 
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With both compounds in hand, biological studies were then performed to 
determine if this particular 15-F2-isoprostane is produced in humans during oxidative 
stress.  The tetradeuterated isoprostane isomer was used as an internal standard in a 
GC/MS assay to detect isoprostanes in human urine.  Data from this study ultimately 
suggested that ent-15-epi-F2t-isoprostane, or its enantiomer, was in fact produced in 
vivo.99 
 Lawson and coworkers100 have proven that the 5-F2-isoprostanes are the most 
abundant F2-isoprostanes found in human urine.  This, along with the previously 
described stereodivergent synthesis of the 15-F2 library, encouraged Pandya and 
Snapper101 to develop a modified strategy to prepare all eight 5-F2-isoprostanes.  As 
depicted in Scheme 3.3, their approached featured a single-pot ROCM of cyclobutenes 
3.12 and 3.07 with ethylene followed by CM with methyl 5-oxohept-6-enoate to generate 
the mono-cross products 3.13 and 3.14, respectively.   
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Scheme 3.3.  Modified synthetic route to a stereodiverse library of 5-F2-isoprostanes. 
After several additional steps, including a selective reduction/resolution strategy to 
produce enantiomerically enriched stereoisomers and an oxidation/olefination protocol to 
introduce the aliphatic side chain, all eight 5-F2-isoprostane regioisomers were each 
synthesized in ten steps (longest linear) from commercially available 4-hydroxy-2-
cyclopentenone (3.11). 
 
Retrosynthetic analysis 
Inspired by our lab’s successful syntheses of isoprostanes, we decided to adapt 
this strategy to synthesize 20-F4t-neuroprostane in an enantioselective manner.  FIGURE 
3.8 illustrates our retrosynthetic analysis of 20-F4t-neuroprostane. 
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Figure 3.8.  Retrosynthetic analysis of 20-F4t-neuroprostane. 
We envisioned that the skipped triene side chain could be installed by a Wittig olefination 
and that the cyclopentane core may be accessed through a modified ROCM/CM route 
using ethyl vinyl ketone as the cross partner.  Adopting a similar reduction/resolution 
protocol could allow for the preparation of an enantiomerically enriched product.  This 
synthetic strategy potentially offers a concise, stereodivergent route to all eight 20-F4-
neuroprostanes (FIGURE 2.6). 
 We later conceived a single-pot, asymmetric double-Wittig olefination as the 
possible key step of our synthesis (FIGURE 3.9).  The one-pot preparation of skipped 
dienes through the use of bis(phosphonium) salts was first reported102 by Wittig himself 
in 1958.  Bestmann et al. modified this strategy to synthesize dissymmetric bis(alkene) 
Lepidoptera pheromones by using two different aldehydes.103   
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Figure 3.9.  Proposed key step: asymmetric single-pot, double-Wittig olefination.  
We devised a modified strategy to prepare the methylene skipped triene through a one-
pot, double-alkenylation involving a highly sensitive #,%-unsaturated aldehyde.  
 
Total synthesis of 20-F4t-neuroprostane 
 As utilized in the preparation of the 15-F2-isoprostane library, our total synthesis 
began by accessing the functionalized cyclobutene 3.16 in four steps from furfuryl 
alcohol (3.15).  This known procedure104,96 (SCHEME 3.4) is technically simple and 
requires inexpensive starting materials, which allows for easy preparation of multi-gram 
quantities of cyclobutene 3.16.  
 
Scheme 3.4.  Four-step synthesis of cyclobutene 3.16.104,96 
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As illustrated in SCHEME 3.5, divinyl intermediate 3.18 was generated by ROCM of 
3.16 in benzene using Grubbs’ 1st generation catalyst (3.17) under an ethylene 
atmosphere.98   
 
Scheme 3.5.  Preparation of divinyl intermediate 3.18 by ROCM. 
Dilution (0.1 M) was necessary to avoid ring-opening metathesis polymerization 
(ROMP) of the starting material (3.16). 
 Using Hovedya-Grubbs’ 2nd generation catalyst (3.19), divinyl compound 3.18 
underwent CM with ethyl vinyl ketone in CH2Cl2 at room temperature (SCHEME 3.6).  
 
Scheme 3.6.  Cross-metathesis protocol for the synthesis of enone 3.20. 
These reaction conditions delivered the desired mono-CM product 3.20 in high 
regioselectivity (none of the undesired mono-CM product was formed) while only a trace 
amount of the double-CM product was observed.  Furthermore, the enone in the desired 
product was obtained exclusively as the E-stereoisomer without any formation of the Z-
alkene.  The high regioselectivity was attributed to possible coordination between 
ruthenium catalyst 3.19 and the free hydroxyl group on the cyclopentane ring (3.18).  
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Perhaps steric hindrance from the TBS protecting group also influences the selectivity of 
the CM.99 
 It is important to note that we opted to use a two-step ROCM/CM procedure 
instead of attempting the ROCM of 3.16 with ethyl vinyl ketone directly.  Shizuka and 
Snapper98 discovered the ROCM of cyclobutene 3.16 with oct-1-en-3-one using 
Hovedya-Grubbs’ 2nd generation catalyst (3.19) failed; they primarily observed ROMP of 
cyclobutene 3.16.  Furthermore, substituting Grubbs’ 1st generation catalyst (3.17) gave 
only unreacted starting material.  Given the precedence99 that both metatheses performed 
optimally under different reaction conditions, we decided to perform these 
transformations in two steps.      
 
Scheme 3.7.  Asymmetric reduction of (±)-3.20 led to the separation of 
diastereomers. 
Subsequently in our synthesis, as shown in SCHEME 3.7, TBS protection of 
enone (±)-3.20 followed by asymmetric catalytic reduction using (R)-(+)-2-methyl-CBS-
oxazaborolidine catalyst (3.21) and catecholborane in toluene gave a pair of 
diastereomers.  After separation of diastereomers using Ag+-impregnated silica gel 
chromatography, the desired enantiomerically enriched allylic alcohol 3.22 was obtained 
in high yield. 
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 Allylic alcohol 3.22 underwent another TBS-protection to prepare for the 
selective hydroboration of the mono-substituted olefin with 9-BBN followed by oxidative 
work-up to give the primary alcohol 3.23 (outlined in SCHEME 3.8).   
 
Scheme 3.8.  Synthesis of aldehyde 3.24: a Wittig olefination precursor. 
Subsequent oxidation with Dess-Martin periodinane (DMP) produced aldehyde 3.24 and 
completed the synthesis of our key Wittig olefination precursor. 
 We then focused our attention on the preparation of the highly sensitive #,%-
unsaturated aldehyde referred to in FIGURE 3.9.  To accomplish this goal, we 
envisioned the oxidation of homoallylic alcohol 3.26, which was prepared from 3-butyn-
1-ol (3.25) by a known procedure in six steps (SCHEME 3.9).105 
 
Scheme 3.9.  Six-step synthesis of homoallylic alcohol 3.26.105 
We found that Dess-Martin periodinane efficiently oxidized the primary alcohol 3.26 to 
the corresponding #,%-unsaturated aldehyde 3.27 (shown in SCHEME 3.10).  Other 
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oxidation conditions, such as the Swern oxidation and TPAP/NMO, produced the 
isomerized ",#-unsaturated aldehyde instead of the desired product. 
 
Scheme 3.10. DMP oxidation to prepare # ,%-unsaturated aldehyde 3.27. 
The key step of our synthesis involved a single-pot, double-Wittig olefination to 
produce tris(TBS-protected) neuroprostane methyl ester 3.30 (illustrated in SCHEME 
3.11).  Our dissymmetric double-Wittig approach began by deprotonation of 
commercially available bis(phosphonium salt) 3.28 with one equivalent of n-BuLi at -78 
°C.  We assumed that, at low temperature, a statistical mixture of the desired mono-ylide 
and undesired bis(ylide) must be formed.  By allowing the reaction mixture to warm to 
room temperature and stir for additional time, we supposed the bis(ylide) was converted 
to the mono-ylide by reacting with remaining bis(phosphonium salt) 3.28.  The solution 
of mono-ylide was re-cooled before aldehyde 3.24 was added and allowed to stir for 9 
hours.  This technique was repeated for the second Wittig olefination involving aldehyde 
3.27 to furnish the tris(TBS-protected) neuroprostane methyl ester 3.30 in an overall 35% 
yield from 3.28 (comparable to yields from similar double-Wittig olefinations106,107). 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
106 “N-(17-Phosphonooxylinolenoyl)glutamine and N-(17-phosphonooxylinoleoyl)glutamine from insect 
gut: The first backbone-phosphorylated fatty acid derivatives in nature” Spiteller, D.; Oldham, N. J.; 
Boland, W. J. Org. Chem. 2004, 69, 1104-1109. 
107 “Synthesis of volicitin: a novel three-component Wittig approach to chiral 17-hydroxylinolenic acid” 
Pohnert, G.; Koch, T.; Boland, W. Chem. Commun. 1999, 12, 1087-1088.!
HO
3.26
MeO2C DMP
O
3.27
MeO2C
CH2Cl2,
0 to 22 °C, 
1 hr
!%"!
 
Scheme 3.11.  Double Wittig reaction to produce tris(TBS-protected) neuroprostane 
methyl ester (3.30). 
 Fluoride-mediated deprotection of all three silyl groups and saponification of the 
methyl ester delivered the desired 20-F4t-neuroprostane and effectively completed the 
first total synthesis of any 20-series neuroprostane (depicted in SCHEME 3.12). 
 
Scheme 3.12.  Completion of 20-F4t-neuroprostane. 
 
Conclusion 
In summary, we achieved the first total synthesis of 20-F4t-neuroprostane through 
a modified ROCM/CM sequence and a one-pot asymmetric double Wittig olefination.  
This 13-step protocol starting from furfuryl alcohol may be adapted to prepare all eight 
members of the 20-F4-neuroprostane family in an enantiomerically enriched manner.  
Lastly, our total synthesis illustrates the highly effective, adaptable nature of the Snapper 
lab’s route toward the preparation of a variety of lipid metabolites. 
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Experimental 
General Information 
 Starting materials and reagents were purchased from commercial suppliers and 
used without further purification unless otherwise noted.  Dichloromethane, diethyl ether, 
benzene, and toluene were dried on alumina columns using a solvent dispensing system.  
Tetrahydrofuran was distilled over sodium metal/benzophenone, and methanol was 
distilled over magnesium methoxide.  Hexanes were distilled over calcium hydride. 
 All reactions were carried out in oven (150 °C, > 4 h) dried or flame-dried 
glassware under an atmosphere of dry nitrogen.  Air/moisture sensitive reagents were 
either transferred in a glovebox or transferred by syringe and added into the reaction 
flasks through rubber septa.  All reactions were allowed to stir with a Teflon covered stir 
bar.  Solvent concentration or removal in vacuo was achieved using a a Büchi rotary 
evaporator.  Flash column chromatography was performed using 60 Å silica gel (230-400 
mesh ASTM).  Phosphomolybdic acid and cerium ammonium molybdate were used as 
staining agents for TLC. 
1H NMR spectra were measured on a Varian Gemini-500 instrument (500 MHz).  
Chemical shifts are reported in ppm downfield from tetramethylsilane with the solvent 
reference as the internal standard (CHCl3: & 7.26 ppm or CD3OD: & 3.34 ppm).  Data are 
reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, qt = quintet, dt = doublet of triplet, m = multiplet, br = broad), 
coupling constants (Hz). 
13C NMR spectra were recorded on a Varian Gemini-500 instrument (125 MHz) 
with complete proton decoupling.  Chemical shifts are reported in ppm downfield from 
!%$!
tetramethylsilane with the solvent reference as the internal standard (CHCl3: & 77.23 ppm 
or CD3OD: & 49.86 ppm). 
Infrared spectra (FTIR) were measured on a Mattson Galaxy Series FTIR 5000 
and reported in wavenumbers (cm-1).  Bands are characterized as broad (br), strong (s), 
medium (m), or weak (w).   
High resolution mass spectrometry (HRMS) was performed by Marek Domin at 
the Mass Spectrometry Center at Boston College. 
  
Experimental Procedure 
 
1-(3-((tert-butyldimethylsilyl)oxy)-5-hydroxy-2-vinylcyclopentyl)pent-1-en-3-one  
(3.20) 
 In a 100 mL roundbottom flask with stir bar, divinyl compound (±)-3.18 (864 mg, 
3.22 mmol) and ethyl vinyl ketone (0.320 mL, 3.22 mmol) were dissolved in CH2Cl2 
(32.2 mL).  Hoveyda-Grubbs second generation catalyst (101 mg, 0.161 mmol) was 
added and the green reaction mixture was allowed to stir under a nitrogen atmosphere at 
room temperature for 3 hours.  Ethyl vinyl ether (4.0 mL) was added and stirred for 5 
minutes. Silica gel (4.0 g) was then added, and the black mixture was allowed to stir for 
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15 minutes.  The solvent was removed in vacuo, and the residue was purified by silica gel 
chromatography (hexanes:EtOAc, 6:1) to afford (±)-3.20 as a light brown oil (471 mg, 
1.45 mmol, 45% yield).  1H NMR (CDCl3, 500 MHz): & 6.67 (1H, dd, J = 15.8, 9.3 Hz), 
6.18 (1H, dd, J = 16.0, 1.0 Hz), 5.52-5.44 (1H, m), 5.07-5.03 (2H, m), 4.12-4.09 (1H, m), 
4.07-4.04 (1H, m), 3.01-2.97 (1H, m), 2.85-2.82 (1H, m), 2.55-2.51 (2H, m), 2.41-2.36 
(2H, m), 1.72 (1H, dt, J = 14.5, 3 Hz), 1.07 (3H, t, J = 7.3 Hz), 0.87 (9H, s), 0.04 (6H, s). 
13C NMR (CDCl3, 125 MHz): & 200.9, 145.4, 136.0, 131.0, 117.6, 76.9, 75.7, 56.6, 53.6, 
43.4, 33.7, 25.9, 18.0, 8.1, -4.6, -4.7.  IR (thin film, KBr): 3492 (b), 2957 (s), 2884 (s), 
2863 (s), 1669 (m), 1627 (m) cm-1.  HRMS (ESI+): calcd for C18H33O3Si [M+H]: 
325.2199, found: 325.2203. 
 
 
1-(3,5-bis((tert-butyldimethylsilyl)oxy)-2-vinylcyclopentyl)pent-1-en-3-ol (3.22) 
 A sealed 25 mL roundbottom flask with stir bar was placed under a nitrogen 
atmosphere and charged sequentially with alcohol (±)-3.20 (561 mg, 1.73 mmol), CH2Cl2 
(6.9 mL), triethylamine (1.21 mL, 8.65 mmol), TBSCl (522 mg, 3.46 mmol), and DMAP 
(106 mg, 0.87 mmol).  The yellow reaction mixture was allowed to stir at room 
temperature under N2 (monitored by TLC).  After 18 hours, the reaction mixture was 
diluted with CH2Cl2 (50 mL) and washed with 1 M HCl (50 mL) then brine (50 mL).  
The aqueous phase was extracted with CH2Cl2 and the combined organic layers were 
dried over MgSO4, filtered, concentrated in vacuo, and purified by silica gel 
1) TBSCl, DMAP, Et3N,
    CH2Cl2, 22 °C, 18 hrs
2) (R)-(+)-2-methyl-CBS-oxazaborolidine,
    catecholborane, toluene, -78 °C, 18 hrs
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chromatography (hexanes: ethyl acetate, 20:1) to obtain bis(TBS-protected) enone (699 
mg, 1.59 mmol, 92% yield) as a clear oil.  A flame-dried 25 mL roundbottom flask with 
stir bar was fitted with a septum, purged with nitrogen, and charged with bis(TBS-
protected) enone (699 mg, 1.59 mmol) and toluene (6.3 mL) then allowed to stir.  The 
colorless solution was cooled to -78 °C and (R)-(+)-2-methyl-CBS-oxazaborolidine 
catalyst (1 M in toluene, 796 µL, 0.796 mmol) was added followed by dropwise addition 
of catecholborane (1.53 g of 50% w/w solution in toluene, 6.37 mmol).  The yellow 
reaction mixture was allowed to stir at -78 °C for 18 hours.  Methanol (2.0 mL) was 
added to quench the reaction, and the mixture was allowed to slowly warm to 23 °C.  The 
solution was diluted with ethyl acetate (50 mL) and washed sequentially with 1 M NaOH 
(2 x 50 mL), 1 M HCl (1 x 50 mL), and brine (1 x 50 mL).  The organic layer was dried 
over MgSO4, filtered, concentrated and purified (separation of diastereomers) by Ag+-
doped silica gel chromatography (10% AgNO3) using hexanes:diethyl ether (5:1 to 3:1 to 
0:1) as eluent.  After concentration and filtration through a short pad (1 cm) of silica gel 
with diethyl ether, 332 mg (0.753 mmol, 95% yield based on racemic starting material) of 
allylic alcohol 3.22 was recovered as a yellow oil. 1H NMR (CDCl3, 500 MHz): & 5.62-
5.43 (3H, m), 5.06-5.04 (1H, m), 5.03-5.01 (1H, m), 3.99 (1H, q, J = 6.5 Hz), 3.95-3.90 
(2H, m), 2.74-2.67 (2H, m), 2.36 (1H, dt, J = 13.5, 6.5 Hz), 1.62-1.50 (3H, m), 1.36 (1H, 
bs), 0.91 (3H, t, J = 7 Hz) 0.87 (18H, s), 0.018 (6H, s), 0.013 (3H, s), 0.005 (3H, s). 13C 
NMR (CDCl3, 125 MHz): & 137.6, 135.2, 130.8, 116.8, 76.2, 76.0, 74.5, 55.5, 53.6, 44.5, 
30.3, 26.0, 18.3, 18.2, 9.9, -4.3, -4.35, -4.4.  IR (thin film, KBr): 3347 (b), 3070 (w), 2956 
(s), 2882 (s), 2863 (s), 1635 (w), 1471 (m), 1463 (m), 1255 (s), 1101 (b), 1064 (b), 836 
(b) cm-1.  HRMS (ESI+): calcd for C24H49O3Si2 [M+H]: 441.3220, found: 441.3229. 
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((4-3-((tert-butyldimethylsilyl)oxy)pent-1-en-1-yl)-5-vinylcyclopentane-1,3-
diyl)bis(oxy))bis(tert-butyldimethylsilane) (3.31) 
 A sealed 25 mL roundbottom flask with stir bar was placed under a nitrogen 
atmosphere and charged sequentially with alcohol 3.22 (156 mg, 0.354 mmol), CH2Cl2 
(1.4 mL), triethylamine (0.25 mL, 1.77 mmol), TBSCl (107 mg, 0.780 mmol), and 
DMAP (21.6 mg, 0.177 mmol).  The yellow reaction mixture was allowed to stir at room 
temperature under N2 (monitored by TLC).  After 24 hours, the reaction mixture was 
diluted with CH2Cl2 (10 mL) and washed with 1 M HCl (10 mL) then brine (10 mL).  
The aqueous phase was extracted with CH2Cl2 and the combined organic layers were 
dried over MgSO4, filtered, concentrated in vacuo, and purified by silica gel 
chromatography (hexanes: ethyl acetate, 16:1) to obtain tris(TBS-protected) diene 3.31 
(195 mg, 0.351 mmol, 99% yield) as a clear oil. 1H NMR (CDCl3, 500 MHz): & 5.64-5.57 
(1H, m), 5.46-5.34 (2H, m), 5.07-5.01 (2H, m), 3.99-3.89 (3H, m), 2.73-2.65 (2H, m), 
2.36 (1H, dt, J = 13.5, 6.5 Hz), 1.62-1.57 (1H, m), 1.51-1.44 (2H, m), 0.89 (9H, s), 0.88 
(9H, s), 0.87 (9H, s), 0.86 (3H, t, J = 7.5 Hz), 0.042 (3H, s), 0.021 (9H, s), 0.017 (3H, s), 
0.011 (3H, s). 13C NMR (CDCl3, 125 MHz): & 137.8, 135.8, 129.0, 116.7, 76.3, 76.1, 
75.1, 55.4, 53.9, 44.6, 31.5, 26.2, 26.1, 18.5, 18.32, 18.27, 9.9, -4.0, -4.315, -4.322, -4.36, 
-4.38, -4.5.  IR (thin film, KBr): 3024 (s), 2957 (b), 2928 (s), 2916 (s), 2885 (b), 2862 (b), 
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1634 (w), 1472 (m), 1463 (m), 1254 (s), 1097 (b), 1065 (b), 1006 (s), 837 (b), 778 (b)  
cm-1.  HRMS (ESI+): calcd for C30H63O3Si3 [M+H]: 555.4085, found: 555.4064. 
 
 
2-(3,5-bis((tert-butyldimethylsilyl)oxy)-2-(3-((tert-butyldimethylsilyl)oxy)pent-1-en-
1-yl)cyclopentyl)ethanol (3.23) 
 In the glovebox, an oven-dried one dram vial with stir bar was charged with 9-
borabicyclo[3.3.1]nonane dimer (145 mg, 0.595 mmol), and dry/degassed THF (1.2 mL).  
The vial was sealed with a rubber septum, removed from the glovebox, and the contents 
were allowed to stir.  After addition of a N2 inlet, the suspension was cooled to 0 °C, and 
diene 3.31 (150 mg, 0.270 mmol) was added.  After 5 minutes, the reaction mixture was 
allowed to warm to 22 °C and stirred for 3 hours.  The reaction mixture was opened to air 
and diluted with ethyl acetate (1.8 mL).  The solution was cooled to 0 °C and charged 
successively with 3 M sodium hydroxide (0.64 mL) and 30% hydrogen peroxide (0.53 
mL).  After 5 minutes, the reaction mixture was allowed to warm to 22 °C and stirred for 
an additional hour.  The mixture was extracted with ethyl acetate (3 x 5 mL), and the 
combined organic layers were washed sequentially with saturated aqueous NaHCO3 (10 
mL) and brine (10 mL), then dried (MgSO4), filtered, and concentrated under reduced 
pressure.  Purification by silica gel chromatography (hexanes:diethyl ether, 7:1 to 5:1)  
afforded 3.23 (151 mg, 0.263 mmol, 98% yield) as a colorless oil. 1H NMR (CDCl3, 500 
TBSO
TBSO
Me
OTBS
3.31
9-BBN, THF; 
NaOH, H2O2
TBSO
TBSO
Me
OTBS
3.23
OH
!%)!
MHz): & 5.43 (1H, dd, J = 15.5, 6.0 Hz), 5.28 (1H, ddd, J = 15.0, 10.0, 0.5 Hz), 3.97 (1H, 
q, J = 6.0 Hz), 3.89-3.83 (2H, m), 3.70-3.58 (2H, m), 2.49 (1H, t, J = 9 Hz), 2.36-2.31 
(1H, m), 2.27-2.21 (1H, m), 2.13 (1H, bs), 1.63-1.51 (3H, m), 1.49-1.44 (2H, m) 0.882 
(9H, s) 0.879 (9H, s), 0.86 (9H, s), 0.84 (3H, t, J = 7.5 Hz), 0.056 (3H, s), 0.051 (3H, s), 
0.031 (3H, s), 0.005 (3H, s), 0.001 (6H, s). 13C NMR (CDCl3, 125 MHz): & 136.0, 128.1, 
77.3, 76.6, 74.5, 62.2, 54.0, 46.2, 44.6, 32.7, 31.5, 26.09, 26.07, 26.06, 18.5, 18.3, 18.2, 
9.8, -3.8, -4.2, -4.4, -4.48, -4.52.  IR (thin film, KBr): 3429 (b), 2960 (w), 2866 (m), 2843 
(m), 1695 (w), 1471 (m), 1463 (m), 1362 (s), 1254 (b), 1091 (b), 1061 (b), 1020 (m), 
1007 (s), 836 (b), 780 (w) cm-1.  HRMS (ESI+): calcd for C30H64O4NaSi3 [M+Na]: 
595.4005, found: 595.4022. 
 
 
2-(3,5-bis((tert-butyldimethylsilyl)oxy)-2-(3-((tert-butyldimethylsilyl)oxy)pent-1-en-
1-yl)cyclopentyl)acetaldehyde (3.24) 
A one dram vial with magnetic stir bar was sealed with a septum, placed under 
N2, and charged with primary alcohol 3.23 (30.0 mg, 52.3 µmol) and dry CH2Cl2 (296 
µL).  The clear solution was allowed to stir, cooled to 0 °C, and Dess-Martin Periodinane 
(0.30 M in CH2Cl2, 227 µL, 68.1 µmol) was added.  After 5 minutes, the reaction mixture 
was allowed to warm to 22 °C and stir for 1.5 hours.  The reaction mixture was cooled to 
0 °C and washed with a saturated aqueous solution (600 µL) of NaHCO3/Na2S2O3 (1:1).  
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After decantation, the aqueous layer was washed with CH2Cl2 (3 x 5 mL).  The combined 
organic layers were dried over MgSO4, filtered, concentrated in vacuo, and purified by 
silica gel chromatography (hexanes:Et2O, 9:1) to give pure 3.24 as a thick yellow oil 
(28.1 mg, 49.2 µmol, 94% yield).  1H NMR (CDCl3, 500 MHz): & 9.74 (1H, t, J = 2.0 
Hz), 5.44 (1H, dd, J = 15.5, 5.5 Hz), 5.25 (1H, ddd, J = 15.5, 9.5, 1.0 Hz), 3.99, 1H, dq, J 
= 6.0, 1.0 Hz), 3.90-3.87 (1H, m), 3.78 (1H, q, J = 8.0 Hz), 2.69-2.64 (2H, m), 2.38-2.30 
(3H, m), 1.58-1.53 (1H, m), 1.49-1.43 (2H, m), 0.89 (9H, s), 0.872 (9H, s), 0.870 (9H, s), 
0.84 (3H, t, J = 7.5 Hz), 0.04 (3H, s), 0.03 (3H, s), 0.023 (3H, s), 0.018 (6H, s), 0.01 (3H, 
s).  13C NMR (CDCl3, 125 MHz): & 202.6, 136.7, 127.3, 76.4, 76.2, 74.2, 52.7, 44.3, 44.2, 
43.9, 31.4, 26.1, 26.0, 18.5, 18.2, 18.1, 9.8, -3.8, -4.1, -4.2,    -4.4, -4.47, -4.51, -4.7.  IR 
(thin film, KBr): 2957 (s), 2890 (s), 2863 (s), 2711 (w), 1729 (w), 1471 (m), 1463 (m), 
1388 (w), 1362 (w), 1254 (s), 1090 (b), 1024 (w), 1007 (m), 836 (b), 779 (m) cm-1.  
HRMS (ESI+): calcd for C30H66NO4Si3 [M+NH4]: 588.42996, found 588.42976. 
 
 
(Z)-methyl 7-hydroxyhept-4-enoate (3.26) 
Homoallylic alcohol 3.26 was prepared in six steps according to the literature.105 1H 
NMR (CDCl3, 500 MHz): & 5.55-5.43 (2H, m), 3.67 (3H, s), 3.65 (2H, t, J = 6.0 Hz), 
2.32-2.24 (6H, m), 1.68 (1H, bs).  13C NMR (CDCl3, 125 MHz): & 173.9, 130.9, 127.4, 
62.3, 51.8, 34.0, 30.1, 22.9.  IR (thin film, KBr): 3424 (b), 3022 (m), 2983 (b), 2925 (m), 
2910 (m), 2896 (m), 2877 (m), 1739 (s), 1656 (w), 1460 (b), 1371 (s), 1342 (b), 1268 
HO CO2Me
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(m), 1160 (b), 1113 (s), 984 (m), 951 (s), 675 (m) cm-1.  HRMS (ESI+): calcd for 
C8H15O3 [M+H]: 159.1021, found 159.1024. 
 
 
(Z)-methyl 7-oxohept-4-enoate (3.27) 
A one dram vial with magnetic stir bar was sealed with a septum, placed under 
N2, and charged with homoallylic alcohol 3.26 (30.0 mg, 190 µmol) and dry CH2Cl2 (1.2 
mL).  The clear solution was allowed to stir, cooled to 0 °C, and Dess-Martin Periodinane 
(0.30 M in CH2Cl2, 760 µL, 228 µmol) was added.  After 5 minutes, the reaction mixture 
was allowed to warm to 22 °C and stir for 1 hour.  The reaction mixture was cooled to 0 
°C and washed with a saturated aqueous solution (3 mL) of NaHCO3/Na2S2O3 (1:1).  
After decantation, the aqueous layer was washed with CH2Cl2 (3 x 5 mL).  The combined 
organic layers were dried over MgSO4 (2 minutes), filtered, and concentrated under 
reduced pressure. Addition of anhydrous benzene followed by removal in vacuo gave dry 
3.27 as a pale yellow oil, which was directly added to the solution of ylid in the next step. 
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(methyl 12-(3,5-bis((tert-butyldimethylsilyl)oxy)-2-(3-((tert-butyldimethylsilyl)oxy) 
pent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoate (3.30) 
To an oven-dried one dram vial with magnetic stir in the glovebox was added 
trimethylenebis(triphenylphosphonium bromide) (42.0 mg, 57.9 µmol) and THF (579 µL, 
0.10 M).  The vial was sealed with a septum, removed from the glovebox, and cooled to  
-78 °C under a positive flow of nitrogen, and n-BuLi (1.60 M in hexanes, 36.0 µL, 57.9 
µmol) was slowly added.  After 5 minutes, the yellow/orange reaction mixture was 
allowed to warm to 22 °C and stir for an additional 30 minutes then re-cooled (-78 °C).  
A solution of the first aldehyde 3.24 (33.0 mg, 57.9 µmol) in THF (58.0 µL, 0.10 M) was 
added dropwise to the red solution of ylid.  After 10 minutes, the yellow/orange reaction 
mixture was allowed to warm to 22 °C and stir for an additional 9 hours.  During this 
time, homoallylic alcohol 3.26 underwent the DMP oxidation described above.  The 
yellow reaction mixture was re-cooled (-78 °C), and n-BuLi (1.60 M in hexanes, 36.0 µL, 
57.9 µmol) was added dropwise.  After 5 minutes, the orange reaction mixture was 
allowed to warm to 22 °C and stir for an additional 30 minutes then re-cooled (-78 °C).  
A solution of the second aldehyde 3.27 (12.0 mg, 76.9 µmol) in THF (77.0 µL, 0.10 M) 
was added dropwise to the red solution of ylid.  After 10 minutes, the yellow/orange 
reaction mixture was allowed to warm to 22 °C and stir for an additional 15 hours.  The 
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yellow reaction was diluted with Et2O (10 mL) and washed with saturated aqueous 
ammonium chloride (10 mL).  The layers were separated, and the aqueous phase was 
extracted with Et2O (3 x 5 mL).  The combined organics were dried over MgSO4, filtered, 
concentrated under reduced pressure, and purified by Ag+-impregnated (10%) silica gel 
chromatography (hexanes:Et2O, 8:1) to give slightly impure tris(TBS-protected)-
neuroprostane methyl ester 3.30 (14.9 mg, 20.3 µmol, 35% yield).  1H NMR (CDCl3, 500 
MHz): & 5.46 (1H, dd, J = 16.0, 6.0 Hz), 5.44-5.30 (7H, m), 3.99 (1H, q, J = 6.0 Hz), 
3.90 (1H, m), 3.80 (1H, q, J = 6.0 Hz), 3.67 (3H, s), 2.84-2.74 (4H, m), 2.64-2.59 (1H, 
m), 2.41-2.29 (4H, m), 2.17-1.90 (4H, m), 1.56-1.47 (3H, m), 0.89 (9H, s), 0.88 (9H, s), 
0.863 (9H, s), 0.857 (3H, t, J = 7.5 Hz), 0.044 (3H, s), 0.030 (3H, s), 0.025 (3H, s), 0.02 
(3H, s), 0.011 (3H, s), 0.007 (3H, s).  13C NMR (CDCl3, 125 MHz): & 173.7, 135.8, 
129.6, 129.3, 128.7, 128.5, 128.4, 128.3, 128.1, 76.4, 76.3, 74.8, 52.5, 51.8, 50.2, 44.6, 
34.5, 34.3, 31.5, 30.5, 29.9, 26.4, 26.10, 26.09, 26.07, 25.9, 25.8, 23.0, 18.5, 18.3, 18.2, 
9.9, -4.1, -4.2, -4.4, -4.5.  IR (thin film, KBr): 3013 (m), 2961 (b), 2883 (b), 2867 (s), 
2842 (m), 1733 (s), 1664 (b), 1471 (s), 1463 (s), 1404 (m), 1388 (s), 1362 (s), 1254 (b), 
1088 (b), 1007 (m), 973 (m), 835 (b), 781 (s) cm-1.  HRMS (ESI+): calcd for 
C41H78O5NaSi3 [M+Na]: 757.5055, found: 757.5034. 
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20-F4t-neuroprostane 
A sealed one dram vial with magnetic stir bar under a positive flow of nitrogen 
was charged with tris(TBS-protected) neuroprostane methyl ester 3.30 (7.0 mg, 9.52 
µmol) and TBAF (1.00 M in THF, 105 µL, 105 µmol).  The yellow/orange reaction 
mixture was allowed to stir at 22 °C overnight.  After 24 hours, the brown reaction 
mixture was diluted with ethyl acetate (10 mL) and washed with saturated aqueous 
ammonium chloride (3 x 5 mL).  The combined aqueous layers were extracted with ethyl 
acetate (4 x 10 mL).  The organic layers were combined, dried (MgSO4), filtered, 
concentrated and purified by silica gel chromatography (8% MeOH in CH2Cl2) to give 
the neuroprostane methyl ester as a slightly yellow oil (3.6 mg, 9.17 µmol, 97% yield).  
To a sealed one dram vial with magnetic stir bar under a positive flow of nitrogen was 
added neuroprostane methyl ester (3.6 mg, 9.17 µmol) and methanol (26.0 µL).  The 
solution was allowed to stir, cooled to 0 °C, and an aqueous solution of LiOH (1.42 M, 
9.0 µL) was added dropwise.  After 5 minutes, the reaction mixture was allowed to stir 
for an addition 4 hours at 22 °C. The reaction mixture was re-cooled (0 °C) and 2% 
aqueous HCl was added dropwise until a pH of 2 was achieved.  The mixture was 
extracted with ethyl acetate (5 x 5 mL), and the combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo.  The yellow residue was purified by silica 
gel chromatography (75% ethyl acetate in hexanes to 100% ethyl acetate to 0.01% AcOH 
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and 5% MeOH in ethyl acetate) to give pure 20-F4t-neuroprostane as a pale yellow oil 
(2.5 mg, 6.61 µmol, 72% yield).  1H NMR (CD3OD, 500 MHz): & 5.55-5.54 (2H, m), 
5.45-5.35 (6H, m), 3.99-3.94 (2H, m), 3.88 (1 H, q, J = 8 Hz), 2.87-2.82 (3H, m), 2.71-
2.68 (1H, m), 2.49 (1H, quintet, J = 7.5 Hz), 2.38-2.32 (4H, m), 2.19-2.06 (4H, m), 1.56-
1.49 (3H, m), 0.91 (3H, t, J = 7.5 Hz).  13C NMR (CD3OD, 125 MHz): & 136.6, 130.4, 
130.2, 130.0, 129.7, 129.5, 129.4, 129.2, 76.4, 76.3, 75.0, 53.7, 51.5, 43.8, 31.4, 27.5, 
26.9, 26.7, 24.1, 10.4.  IR (thin film, KBr): 3384 (b), 3330 (b), 3249 (b), 3059 (w), 3031 
(w), 3015 (b), 2960 (s), 2926 (w), 2896 (m), 2884 (s), 2873 (s), 1722 (s), 1712 (b), 1667 
(m), 1462 (m), 1435 (m), 1413 (m), 1379 (w), 1260 (s), 1090 (b), 1062 (s), 1024 (m), 974 
(w), 800 (b), 746 (m), 701 (m) cm-1.  HRMS (ESI+): calcd for C22H34O5Na [M+Na]: 
401.2304, found: 401.2289. 
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